Paroxysmal nocturnal haemoglobinuria (PNH) is a disorder resulting from erythrocyte membrane deficiencies caused by PIG-A gene mutations. While current treatments alleviate symptoms, they fail to address the underlying cause of the disease-the pathogenic PNH clones. In this study, we found that the expression of carbamoyl phosphate synthetase 1 (CPS1) was downregulated in PNH clones, and the level of CPS1 was negatively correlated with the proportion of PNH clones. Using PIG-A knockout K562 (K562 KO) cells, we demonstrated that CPS1 knockdown increased cell proliferation and altered cell metabolism, suggesting that CPS1 participates in PNH clonal proliferation through metabolic reprogramming. Furthermore, we observed an increase in the expression levels of the histone demethylase JMJD1C in PNH clones, and JMJD1C expression was negatively correlated with CPS1 expression. Knocking down JMJD1C in K562 KO cells upregulated CPS1 and H3K36me3 expression, decreased cell proliferation and increased cell apoptosis. Chromatin immunoprecipitation analysis further demonstrated that H3K36me3 regulated CPS1 expression. Finally, we demonstrated that histone demethylase inhibitor JIB-04 can suppressed K562 KO cell proliferation and reduced the proportion of PNH clones in PNH mice. In conclusion, aberrant regulation of the JMJD1C-H3K36me3-CPS1 axis contributes to PNH clonal proliferation. Targeting JMJD1C with a specific inhibitor unveils a potential strategy for treating PNH patients.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.19477DOI Listing

Publication Analysis

Top Keywords

pnh clones
20
histone demethylase
12
cps1 expression
12
cell proliferation
12
pnh
10
demethylase jmjd1c
8
cps1
8
paroxysmal nocturnal
8
nocturnal haemoglobinuria
8
metabolic reprogramming
8

Similar Publications

PIGA mutation cannot fully explain the proliferative advantage of abnormal clones and thrombosis tendency in paroxysmal nocturnal haemoglobinuria (PNH), and additional genes may play a role, justifying further investigation. CD59+ and CD59- peripheral blood mononuclear cells from six PNH patients were sorted and subjected to whole-exon sequencing (WES) and whole-transcriptome sequencing respectively. Six age- and sex-matched healthy volunteers were enrolled as controls.

View Article and Find Full Text PDF

Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus.

Int J Mol Sci

November 2024

Cancer Center, Division of Hematology and Oncology, Department of Medicine, Taipei Municipal Wanfang Hospital, Taipei Medical University, No. 111, Section 3, Xinglong Rd, Wenshan District, Taipei City 11696, Taiwan.

Paroxysmal nocturnal hemoglobinuria (PNH) clones can be identified in a significant proportion of patients with aplastic anemia (AA). Screening for PNH clones at the time of an AA diagnosis is recommended by national and international guidelines. In this report, an expert panel of physicians discusses current best practices and provides recommendations for managing PNH in patients with AA in the Asia-Pacific region.

View Article and Find Full Text PDF
Article Synopsis
  • * Results showed stable health markers (LDH, hemoglobin, reticulocytes) throughout the study, with no significant differences in kidney disease rates or need for blood transfusions among patients.
  • * The findings indicate that the biosimilar is both effective and safe for long-term use in PNH patients, with only a low incidence of adverse reactions reported.
View Article and Find Full Text PDF
Article Synopsis
  • FLAER (Fluorescently labeled aerolysin) is used to identify PNH clones in blood samples, but there's limited information on its expression in normal bone marrow cells.
  • This study analyzed 54 bone marrow samples from various conditions, including PNH and different types of leukemia, to understand FLAER expression in both normal and diseased hematopoiesis.
  • Results showed that while FLAER intensity was generally intermediate in stem cells, a specific FLAER-negative subgroup was found in PNH patients, indicating varying expression levels in myeloid precursors across different conditions.
View Article and Find Full Text PDF
Article Synopsis
  • * Immunosuppressive therapies (IST) are particularly beneficial for patients with lower-risk MDS, especially those with certain bone marrow characteristics.
  • * Accurately diagnosing lower-risk MDS can be challenging and requires careful evaluation of the bone marrow, with IST recommended as the first-line treatment for those showing signs of immune-related bone marrow failure.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!